Here's Why Jim Cramer Is Excited About Stryker (SYK) Expanding Beyond Surgical Robotics
Biopharmaceutical newcomer Intra-Cellular surged over 25% before the market opened! It is reported that Johnson & Johnson is in talks to acquire the company, reigniting a wave of Medical mergers and acquisitions.
Johnson & Johnson is in talks to acquire the biopharmaceutical company Intra-Cellular Therapies Inc., which focuses on treating central nervous system diseases, and both parties may reach an agreement as early as this week.
Taking a stroll becomes a sensation! Siasun Robot&Automation from Shenzhen is popular both domestically and internationally, with NVIDIA experts also giving their thumbs up.
After the robotic dog from Yushu Technology became a sensation online, the humanoid robots from Siasun Robot&Automation have also gained immense popularity overseas.
Major signal? Huang Renxun announces NVIDIA's latest breakthrough in the field of physical AI.
Jensen Huang's latest speech sends a significant signal.
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
New progress! The OpenAI robot project is recruiting, or developing its own Sensors.
① Kalinowski focused on introducing the three positions of the OpenAI Robot&Automation team and their specific responsibilities, including Electronic Perception Engineer, Robot Machinery Design Engineer, and Technical Project Manager; ② The OpenAI team will independently develop Sensors and computational components, powered by OpenAI's in-house AI models.
The humanoid robot standing next to Jensen Huang is entering the ChatGPT moment.
This is an important breakthrough for embodied intelligence because it helps Siasun Robot&Automation tackle one of the biggest bottlenecks on the path to generalization: the problem of 'scarcity of high-quality data,' creating realistic environments and perceiving objects for humanoid robots.
Key Deals This Week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and More
Express News | CITIC SEC: The year of mass production for Optimus is expected to inject strong confidence into the humanoid robot Sector.
Unpleasant Surprises Could Be In Store For Stryker Corporation's (NYSE:SYK) Shares
Bernstein Adjusts Price Target on Stryker to $425 From $410, Keeps Outperform Rating
Musk: The goal this year is to produce thousands of Siasun Robot&Automation humanoid robots, with production increasing tenfold each year over the next two years.
Musk stated that if everything goes smoothly, the production of humanoid robots will increase tenfold by 2026, with the goal of producing between 0.05 million to 0.1 million humanoid robots next year, and then increasing it tenfold again the following year.
Bernstein Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $425
Bernstein Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $410
A Quick Look at Today's Ratings for Stryker Corp(SYK.US), With a Forecast Between $394 to $450
NVIDIA open-sources the world's foundational models, humanoid robots accelerate towards the 'ChatGPT moment'.
① Recently, NVIDIA launched the physical AI model Cosmos, which is capable of predicting environments such as warehouses and road conditions to train Siasun Robot&Automation; ② According to NVIDIA's disclosed list, the first batch of users for Cosmos includes manufacturers such as 1X, Agility, Figure AI, and Xiaopeng Autos; ③ Brokerages believe that in the collection methods of training data for humanoid robots, synthetic data will greatly promote the development of robots.
BTIG Sticks to Their Buy Rating for Stryker (SYK)
The medical device company Stryker plans to acquire Inari for 4.9 billion US dollars.
On January 8, Glonghui reported that the medical device manufacturer Stryker announced it would acquire Inari Medical at a price of $80 per share, with a total transaction amount of approximately $4.9 billion. Stryker produces a variety of medical products, from hospital beds and other furniture to cleaning products, as well as orthopedic and neuro-surgical tools. Inari focuses on diseases such as venous thromboembolism or patients' venous thrombus, providing surgical products.
Penumbra Spikes After Stryker- Inari Deal
JMP Securities Reiterates Market Perform on Strykerto Market Perform